Although the benefits of NHT in patients with advanced PC include local control of the primary disease site with pathological complete remission and systemic control of microscopic metastases, they do not translate to better disease-free survival rates (assessed as lack of BCR or clinical progression) or overall survival rates [15]. Here, BCR is linked to pachyonychia congenita.